Lipitor Lawsuits Continue to Be Filed in South Carolina Litigation, Bernstein Liebhard LLP Reports
The Firm is actively investigating Lipitor lawsuits on behalf of individuals who allegedly developed Type 2 diabetes due to their use of the cholesterol-lowering statin.
(PRWEB) July 20, 2014
Lipitor lawsuits (http://www.thelipitorlawsuit.com/) alleging similar injuries caused by the cholesterol-lowering statin are being filed by the dozens in a federal multidistrict litigation underway in the U.S. District Court, District of South Carolina, Bernstein Liebhard LLP reports.
According to documents published on July 15th, a total of 959 claims are now pending in the federal proceeding, which was established for Lipitor claims that similarly allege new-onset Type 2 diabetes caused by the cholesterol medication. Plaintiffs in these cases accuse Pfizer, Inc. of failing to adequately warn about this side effect in its marketing of Lipitor. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502)
“On a regular basis, our Firm hears from individuals who allegedly developed Type 2 diabetes after taking Lipitor. We are pleased to see this litigation continuing to move forward,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free and confidential case evaluations to individuals who may have sustained injuries caused by Lipitor.
Court records indicate that concerns about the alleged association between Lipitor and diabetes have grown steadily since February 2012, when the U.S. Food and Drug Administration (FDA) warned that all statin manufacturers, including Pfizer, update their product labeling to include information about the risk for this disease. Preceding the FDA alert were the findings of a January 2012 study in JAMA: Internal Medicine that women taking Lipitor or another stain may run an increased risk for Type 2 diabetes.*
Lipitor lawsuits now filed in South Carolina federal court allege that Pfizer's adjusted Lipitor labeling in February 2012 did not suffice, and that patients were still not properly warned about its potential to cause diabetes. They also accuse the company of knowing about this risk prior to February 2012, and withholding it from the public to protect market share.
Alleged victims of Lipitor and diabetes may be entitled to compensation from Pfizer, Inc. for their injury-related damages. To learn more about the possible association between Lipitor and diabetes, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to obtain a free legal review.
*archinte.jamanetwork.com/article.aspx?articleid=1108676, JAMA Internal Medicine, January 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993? As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
For the original version on PRWeb visit: http://www.prweb.com/releases/lipitor-lawsuit/lipitor-diabetes/prweb12030612.htmView Comments and Join the Discussion!